Abstract:Rheumatoid arthritis (RA), one of the systemic autoimmune diseases, features dysregulated inflammation that can eventually lead to multi-joint destruction and deformity. Although current clinical RA treatment agents including non-steroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, and biological agents can alleviate symptoms, there can be long-term drug dependence and considerable side effects. To promote the course of RA from inflammation to resolution and ultimately terminate the vicious cycle of recrudescence, it is important to regulate the pro-/anti- inflammatory abilities of macrophages for constructing an immunosuppressive or anti-inflammatory microenvironment. Macrophage-derived exosomes can be homed or targeted to inflammatory tissues or cells; However, the insufficient anti-inflammatory abilities and intrinsic off-target effects of these exosomes often result in unsatisfying treatment effects, which remains a challenge in the treatment of RA. Here, we proposed a novel kind of inherent anti-inflammatory exosomes (AI-Exo), which was prepared via integrating RAW264.7 macrophage-derived exosomes and a powerful anti-inflammatory immune modulator interleukin-10 by an electroporation method. Then, non-invasive ultrasound was used to increase the permeability of blood vessels and augment the targeted accumulation of AI-Exo to inflammatory tissues, which could promote macrophages polarization to M2 phenotypes, relieve inflammation symptoms, propel resolution, and accelerate tissue repair against collagen-induced arthritis. This work intensely supports that ultrasound-augmented AI-Exo has significant targeted anti-inflammatory therapeutic effects, and the combined mechanism of anti-inflammation and pro-resolution renders unique insights into the treatment of not only RA but also other inflammatory diseases, which provides an effective strategy and a promising prospect for future wider biomedical applications and clinical transformations.

Decoy Interleukin-1 Receptor Antagonist on Extracellular Vesicles

IL-1Ra and its Delivery Strategies: Inserting the Association in Perspective

Selective Delivery of Interleukine-1 Receptor Antagonist to Inflamed Joint by Albumin Fusion

Replenishing Decoy Extracellular Vesicles Inhibits Phenotype Remodeling of Tissue-Resident Cells in Inflammation-Driven Arthritis.

Interleukin-1 Receptor Antagonist: A New Therapy for Type 2 Diabetes Mellitus

Controlled Release of Interleukin-1 Receptor Antagonist from Hyaluronic Acid-Chitosan Microspheres Attenuates Interleukin-1β-Induced Inflammation and Apoptosis in Chondrocytes.

Development of Dextran Microparticles Loaded with IL-1Ra of High-Encapsulation Efficiency and High-Bioactivity by a Novel Method Without Exposing IL-1Ra to Water–oil Interfaces

Chitosan/hyaluronic Acid/plasmid-Dna Nanoparticles Encoding Interleukin-1 Receptor Antagonist Attenuate Inflammation in Synoviocytes Induced by Interleukin-1 Beta

A CC' loop decoy peptide blocks the interaction between Act1 and IL-17RA to attenuate IL-17- and IL-25-induced inflammation.

Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8

A Targeted Exosome Therapeutic Confers Both Cfdna Scavenging and Macrophage Polarization for Ameliorating Rheumatoid Arthritis

Ultrasound-augmented anti-inflammatory exosomes for targeted therapy in rheumatoid arthritis

[Using Process of Refolding the Protein to Obtain Recombinant Human Interleukin-1 Receptor Antagonist].

Engineering Efferocytosis‐Mimicking Nanovesicles to Regulate Joint Anti‐Inflammation and Peripheral Immunosuppression for Rheumatoid Arthritis Therapy

Exosome-based biomimetic nanoparticles targeted to inflamed joints for enhanced treatment of rheumatoid arthritis

Biscarbamate cross-linked low molecular weight PEI for delivering IL-1 receptor antagonist gene to synoviocytes for arthritis therapy

DAP1-2: a synthetic peptide targeting IL-1R1 receptor effectively suppresses IL-1β in vitro

Pharmacological Efficacy of Anti-Il-1β Scfv, Fab and Full-Length Antibodies in Treatment of Rheumatoid Arthritis.

M2-type exosomes nanoparticles for rheumatoid arthritis therapy via macrophage re-polarization

Bioinspired nanogels as cell-free DNA trapping and scavenging organelles for rheumatoid arthritis treatment

TRAIL-expressing Cell Membrane Nanovesicles As an Anti-Inflammatory Platform for Rheumatoid Arthritis Therapy.